Background The management of metastatic breast cancer requires monitoring of the tumor
burden to determine the response to treatment, and improved biomarkers are needed. …

Improvements in genomic and molecular methods are expanding the range of potential
applications for circulating tumour DNA (ctDNA), both in a research setting and as a 'liquid biopsy…

Cancers acquire resistance to systemic treatment as a result of clonal evolution and
selection 1 , 2 . Repeat biopsies to study genomic evolution as a result of therapy are difficult, …

p53 is a potent tumor suppressor, whose biological effects are largely due to its function as
a transcriptional regulator. Here we report that, in addition to regulating the expression of …

Plasma of cancer patients contains cell-free tumor DNA that carries information on tumor
mutations and tumor burden. Individual mutations have been probed using allele-specific …

The genomic landscape of breast cancer is complex, and inter-and intra-tumour heterogeneity
are important challenges in treating the disease. In this study, we sequence 173 genes in …

The quantitative relation between transcription factor concentrations and the rate of protein
production from downstream genes is central to the function of genetic networks. Here we …

MicroRNAs (miRNAs) belong to a class of noncoding, regulatory RNAs that is involved in
oncogenesis and shows remarkable tissue specificity. Their potential for tumor classification …

The tumor suppressor p53, one of the most intensely investigated proteins 1 , 2 , 3 , 4 , 5 , is
usually studied by experiments that are averaged over cell populations, potentially masking …

Cells regulate gene expression using networks of transcription interactions; it is of interest to
discover the principles that govern the dynamical behavior of such networks. An important …